Huahai Pharmaceutical H1 Net Profit 771 Million Yuan, Up 88.26%

Huahai Pharmaceutical disclosed its 2026 semi-annual report on August 26. In the first half of the year, the company achieved operating revenue of 4.913 billion yuan, up 8.78% year-on-year; net profit attributable to shareholders of the listed company was 771 million yuan, up 88.26% year-on-year; basic earnings per share were 0.52 yuan.

During the reporting period, the company's sales revenue increased year-on-year. In addition, after winning the valsartan European arbitration, the fees paid by Sandoz to the company, including lawyer fees and arbitration fees, had a positive impact on profit.